{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:29:28Z","timestamp":1785767368926,"version":"3.56.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"DOI":"10.1007\/s00345-025-06025-1","type":"journal-article","created":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T10:03:56Z","timestamp":1761991436000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Epidemiology, treatment patterns and effectiveness of adherence to Bacillus Calmette-Gu\u00e9rin therapy in intermediate and high-risk non-muscle-invasive bladder cancer patients: a retrospective cohort analysis using German health claims data"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5990-7534","authenticated-orcid":false,"given":"Jaime","family":"Luna","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9741-1193","authenticated-orcid":false,"given":"Eveline Otte im","family":"Kampe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8765-9881","authenticated-orcid":false,"given":"Heja","family":"Aga-Barfknecht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8435-1374","authenticated-orcid":false,"given":"Moritz","family":"Lehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5305-9805","authenticated-orcid":false,"given":"Leonie","family":"Kunk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-6368-0791","authenticated-orcid":false,"given":"Ivonne","family":"H\u00e4nsel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0726-8590","authenticated-orcid":false,"given":"Saskia","family":"Trescher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-6693","authenticated-orcid":false,"given":"Antje","family":"Mevius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1486-8795","authenticated-orcid":false,"given":"Agnes","family":"Kisser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6659-1374","authenticated-orcid":false,"given":"Nils","family":"Kroeger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4969-0877","authenticated-orcid":false,"given":"Maria","family":"De Santis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,1]]},"reference":[{"key":"6025_CR1","doi-asserted-by":"publisher","first-page":"229","DOI":"10.3322\/caac.21834","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al (2024) Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 74:229\u2013263. https:\/\/doi.org\/10.3322\/caac.21834","journal-title":"CA Cancer J Clin"},{"key":"6025_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medsci8010015","volume":"8","author":"K Saginala","year":"2020","unstructured":"Saginala K, Barsouk A, Aluru JS et al (2020) Epidemiology of bladder cancer. Med Sci Basel Switz 8:15. https:\/\/doi.org\/10.3390\/medsci8010015","journal-title":"Med Sci Basel Switz"},{"key":"6025_CR3","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN et al (2025) Cancer statistics, 2025. CA Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"CA Cancer J Clin"},{"key":"6025_CR4","doi-asserted-by":"publisher","first-page":"1170124","DOI":"10.3389\/fonc.2023.1170124","volume":"13","author":"K Grabe-Heyne","year":"2023","unstructured":"Grabe-Heyne K, Henne C, Mariappan P et al (2023) Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs. Front Oncol 13:1170124. https:\/\/doi.org\/10.3389\/fonc.2023.1170124","journal-title":"Front Oncol"},{"key":"6025_CR5","unstructured":"Robert Koch Institute German Cancer Research Center (2022) Krebs - Bladder cancer. https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Cancer_sites\/Bladder_cancer\/bladder_cancer_node.html. Accessed 7 Apr 2025"},{"key":"6025_CR6","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, B\u00f6hle A, Burger M et al (2017) EAU guidelines on Non-Muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461. https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","journal-title":"Eur Urol"},{"key":"6025_CR7","unstructured":"(2020) Leitlinienprogramm onkologie: Harnblasenkarzinom. S3-Leitlinie Fr\u00fcherkennung, Diagnose, Therapie und Nachsorge des Harnblasenkarzinoms"},{"key":"6025_CR8","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","volume":"81","author":"M Babjuk","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O et al (2022) European association of urology guidelines on Non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in Situ). Eur Urol 81:75\u201394. https:\/\/doi.org\/10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"6025_CR9","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","volume":"33","author":"T Powles","year":"2022","unstructured":"Powles T, Bellmunt J, Comperat E et al (2022) Bladder cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up\u2606. Ann Oncol 33:244\u2013258. https:\/\/doi.org\/10.1016\/j.annonc.2021.11.012","journal-title":"Ann Oncol"},{"key":"6025_CR10","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/S0022-5347(05)64043-8","volume":"169","author":"A B\u00f6hle","year":"2003","unstructured":"B\u00f6hle A, Jocham D, Bock PR (2003) Intravesical Bacillus Calmette-Guerin versus mitomycin C for superficial bladder cancer: a formal meta-analysis of comparative studies on recurrence and toxicity. J Urol 169:90\u201395. https:\/\/doi.org\/10.1016\/S0022-5347(05)64043-8","journal-title":"J Urol"},{"key":"6025_CR11","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/S0022-5347(05)64273-5","volume":"168","author":"RJ Sylvester","year":"2002","unstructured":"Sylvester RJ, van der MEIJDEN APM, Lamm DL (2002) Intravesical Bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials. J Urol 168:1964\u20131970. https:\/\/doi.org\/10.1016\/S0022-5347(05)64273-5","journal-title":"J Urol"},{"key":"6025_CR12","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1016\/j.eururo.2012.10.039","volume":"63","author":"J Oddens","year":"2013","unstructured":"Oddens J, Brausi M, Sylvester R et al (2013) Final results of an EORTC-GU cancers group randomized study of maintenance Bacillus Calmette-Gu\u00e9rin in intermediate- and high-risk Ta, T1 papillary carcinoma of the urinary bladder: one-third dose versus full dose and 1 year versus 3 years of maintenance. Eur Urol 63:462\u2013472. https:\/\/doi.org\/10.1016\/j.eururo.2012.10.039","journal-title":"Eur Urol"},{"key":"6025_CR13","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/s0302-2838(03)00357-9","volume":"44","author":"APM van der Meijden","year":"2003","unstructured":"van der Meijden APM, Sylvester RJ, Oosterlinck W et al (2003) Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European organisation for research and treatment of cancer Genito-Urinary group phase III trial. Eur Urol 44:429\u2013434. https:\/\/doi.org\/10.1016\/s0302-2838(03)00357-9","journal-title":"Eur Urol"},{"key":"6025_CR14","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1111\/bju.12012","volume":"112","author":"JA Witjes","year":"2013","unstructured":"Witjes JA, Palou J, Soloway M et al (2013) Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of Bacillus Calmette-Gu\u00e9rin (BCG): results of an international individual patient data survey (IPDS). BJU Int 112:742\u2013750. https:\/\/doi.org\/10.1111\/bju.12012","journal-title":"BJU Int"},{"key":"6025_CR15","doi-asserted-by":"publisher","first-page":"e213800","DOI":"10.1001\/jamanetworkopen.2021.3800","volume":"4","author":"SB Williams","year":"2021","unstructured":"Williams SB, Howard LE, Foster ML et al (2021) Estimated costs and Long-term outcomes of patients with High-Risk Non\u2013Muscle-Invasive bladder cancer treated with Bacillus Calmette-Gu\u00e9rin in the veterans affairs health system. JAMA Netw Open 4:e213800. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.3800","journal-title":"JAMA Netw Open"},{"key":"6025_CR16","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","volume":"34","author":"AM Kamat","year":"2016","unstructured":"Kamat AM, Sylvester RJ, B\u00f6hle A et al (2016) Definitions, end Points, and clinical trial designs for Non-Muscle-Invasive bladder cancer: recommendations from the international bladder cancer group. J Clin Oncol Off J Am Soc Clin Oncol 34:1935\u20131944. https:\/\/doi.org\/10.1200\/JCO.2015.64.4070","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"6025_CR17","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.zefq.2014.08.022","volume":"108","author":"E Swart","year":"2014","unstructured":"Swart E, Schmitt J (2014) STandardized reporting of secondary data analyses (STROSA) - Vorschlag f\u00fcr Ein berichtsformat f\u00fcr Sekund\u00e4rdatenanalysen. Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen 108:511\u2013516. https:\/\/doi.org\/10.1016\/j.zefq.2014.08.022","journal-title":"Z F\u00fcr Evidenz Fortbild Qual Im Gesundheitswesen"},{"key":"6025_CR18","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1097\/JU.0000000000003459","volume":"209","author":"EC Zabor","year":"2023","unstructured":"Zabor EC, Assel M (2023) On the need for landmark analysis or time dependent covariates. J Urol 209:1060\u20131062. https:\/\/doi.org\/10.1097\/JU.0000000000003459","journal-title":"J Urol"},{"key":"6025_CR19","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s12350-019-01624-z","volume":"26","author":"CJ Morgan","year":"2019","unstructured":"Morgan CJ (2019) Landmark analysis: A primer. J Nucl Cardiol 26:391\u2013393. https:\/\/doi.org\/10.1007\/s12350-019-01624-z","journal-title":"J Nucl Cardiol"},{"key":"6025_CR20","doi-asserted-by":"publisher","first-page":"7655","DOI":"10.1038\/s41598-025-92033-5","volume":"15","author":"X Su","year":"2025","unstructured":"Su X, Tao Y, Chen F et al (2025) Trends in the global, regional, and National burden of bladder cancer from 1990 to 2021: an observational study from the global burden of disease study 2021. Sci Rep 15:7655. https:\/\/doi.org\/10.1038\/s41598-025-92033-5","journal-title":"Sci Rep"},{"key":"6025_CR21","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1093\/ije\/dyw044","volume":"45","author":"FH van Osch","year":"2016","unstructured":"van Osch FH, Jochems SH, van Schooten F-J et al (2016) Quantified relations between exposure to tobacco smoking and bladder cancer risk: a meta-analysis of 89 observational studies. Int J Epidemiol 45:857\u2013870. https:\/\/doi.org\/10.1093\/ije\/dyw044","journal-title":"Int J Epidemiol"},{"key":"6025_CR22","doi-asserted-by":"crossref","unstructured":"Silverman DT, Koutros S, Figueroa JD et al (2017) Bladder cancer. In: Schottenfeld and Fraumeni Cancer Epidemiology and Prevention, Fourth Edition. Oxford University Press, pp 977\u2013996","DOI":"10.1093\/oso\/9780190238667.003.0052"},{"key":"6025_CR23","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.eururo.2016.06.010","volume":"71","author":"S Antoni","year":"2017","unstructured":"Antoni S, Ferlay J, Soerjomataram I et al (2017) Bladder cancer incidence and mortality: A global overview and recent trends. Eur Urol 71:96\u2013108. https:\/\/doi.org\/10.1016\/j.eururo.2016.06.010","journal-title":"Eur Urol"},{"key":"6025_CR24","unstructured":"Robert Koch Institute German Cancer Research Center Bladder Cancer Statistics. Cancer in Germany 2019\/2020. https:\/\/www.krebsdaten.de\/Krebs\/EN\/Content\/Cancer_sites\/Bladder_cancer\/bladder_cancer_node.html"},{"key":"6025_CR25","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrurol.2015.58","volume":"12","author":"AM Kamat","year":"2015","unstructured":"Kamat AM, Flaig TW, Grossman HB et al (2015) Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12:225\u2013235. https:\/\/doi.org\/10.1038\/nrurol.2015.58","journal-title":"Nat Rev Urol"},{"key":"6025_CR26","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1016\/j.eursup.2008.07.009","volume":"7","author":"D Lamm","year":"2008","unstructured":"Lamm D, Colombel M, Persad R et al (2008) Clinical practice recommendations for the management of Non\u2013Muscle invasive bladder cancer. Eur Urol Suppl 7:651\u2013666. https:\/\/doi.org\/10.1016\/j.eursup.2008.07.009","journal-title":"Eur Urol Suppl"},{"key":"6025_CR27","doi-asserted-by":"publisher","first-page":"109","DOI":"10.36469\/001c.124208","volume":"11","author":"FD Gaylis","year":"2024","unstructured":"Gaylis FD, Emond B, Manceur AM et al (2024) Adherence to First-Line intravesical Bacillus Calmette-Gu\u00e9rin therapy in the context of guideline recommendations for US patients with High-Risk Non-muscle invasive bladder cancer. J Health Econ Outcomes Res 11:109\u2013117. https:\/\/doi.org\/10.36469\/001c.124208","journal-title":"J Health Econ Outcomes Res"},{"key":"6025_CR28","doi-asserted-by":"publisher","first-page":"e16584","DOI":"10.1200\/JCO.2024.42.16_suppl.e16584","volume":"42","author":"R Sun","year":"2024","unstructured":"Sun R, Linghu B, Somer RA et al (2024) Treatment patterns with intravesical Bacillus Calmette-Gu\u00e9rin (BCG) in patients with non-muscle-invasive bladder cancer (NMIBC): A real-world data analysis. J Clin Oncol 42:e16584\u2013e16584. https:\/\/doi.org\/10.1200\/JCO.2024.42.16_suppl.e16584","journal-title":"J Clin Oncol"},{"key":"6025_CR29","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1200\/JCO.2025.43.5_suppl.717","volume":"43","author":"J Bedke","year":"2025","unstructured":"Bedke J, Eccleston A, Brinkmann J et al (2025) Global real-world patients characteristics, treatment patterns, and impact of BCG shortage in patients with high-risk non-muscle invasive bladder cancer. J Clin Oncol 43:717\u2013717. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.717","journal-title":"J Clin Oncol"},{"key":"6025_CR30","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1200\/JCO.2023.41.6_suppl.473","volume":"41","author":"AA Petrilla","year":"2023","unstructured":"Petrilla AA, Silverstein AR, Eccleston A et al (2023) Time to event following Bacillus Calmette-Guerin therapy initiation in medicare beneficiaries with intermediate- to high-risk non-muscle invasive bladder cancer, 2010\u20132019. J Clin Oncol 41:473\u2013473. https:\/\/doi.org\/10.1200\/JCO.2023.41.6_suppl.473","journal-title":"J Clin Oncol"},{"key":"6025_CR31","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1200\/JCO.2025.43.5_suppl.730","volume":"43","author":"A Eccleston","year":"2025","unstructured":"Eccleston A, Koshy A, Musat MG et al (2025) Bacillus Calmette-Gu\u00e9rin (BCG) treatment patterns and real-world outcomes in high-risk (HR) non-muscle-invasive bladder cancer (NMIBC): A systematic literature review (SLR). J Clin Oncol 43:730\u2013730. https:\/\/doi.org\/10.1200\/JCO.2025.43.5_suppl.730","journal-title":"J Clin Oncol"},{"key":"6025_CR32","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.purol.2019.11.003","volume":"30","author":"S Jeglinschi","year":"2020","unstructured":"Jeglinschi S, Schirmann A, Durand M et al (2020) Factors affecting guideline adherence in the initial treatment of non-muscle invasive bladder cancer: retrospective study in a French peripheral hospital. Prog En Urol 30:26\u201334. https:\/\/doi.org\/10.1016\/j.purol.2019.11.003","journal-title":"Prog En Urol"},{"key":"6025_CR33","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/CEOR.S274951","volume":"12","author":"LJ Lee","year":"2020","unstructured":"Lee LJ, Kwon CS, Forsythe A et al (2020) Humanistic and economic burden of Non-Muscle invasive bladder cancer: results of two systematic literature reviews. Clin Outcomes Res CEOR 12:693\u2013709. https:\/\/doi.org\/10.2147\/CEOR.S274951","journal-title":"Clin Outcomes Res CEOR"},{"key":"6025_CR34","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1159\/000430501","volume":"96","author":"V Serretta","year":"2016","unstructured":"Serretta V, Scalici Gesolfo C, Alonge V et al (2016) Does the compliance to intravesical BCG differ between common clinical practice and international multicentric. Trials? Urol Int 96:20\u201324. https:\/\/doi.org\/10.1159\/000430501","journal-title":"Trials? Urol Int"},{"key":"6025_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1016\/j.eururo.2018.02.014","volume":"73","author":"MGK Cumberbatch","year":"2018","unstructured":"Cumberbatch MGK, Foerster B, Catto JWF et al (2018) Repeat transurethral resection in Non-muscle-invasive bladder cancer: A systematic review. Eur Urol 73:925\u2013933. https:\/\/doi.org\/10.1016\/j.eururo.2018.02.014","journal-title":"Eur Urol"},{"key":"6025_CR36","doi-asserted-by":"publisher","first-page":"E306","DOI":"10.5489\/cuaj.1514","volume":"8","author":"M Bishr","year":"2014","unstructured":"Bishr M, Lattouf J-B, Latour M, Saad F (2014) Tumour stage on re-staging transurethral resection predicts recurrence and progression-free survival of patients with high-risk non-muscle invasive bladder cancer. Can Urol Assoc J J Assoc Urol Can 8:E306\u2013310. https:\/\/doi.org\/10.5489\/cuaj.1514","journal-title":"Can Urol Assoc J J Assoc Urol Can"},{"key":"6025_CR37","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1007\/s00345-018-2299-2","volume":"36","author":"J Palou","year":"2018","unstructured":"Palou J, Pisano F, Sylvester R et al (2018) Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. World J Urol 36:1621\u20131627. https:\/\/doi.org\/10.1007\/s00345-018-2299-2","journal-title":"World J Urol"},{"key":"6025_CR38","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/s0302-2838(02)00068-4","volume":"41","author":"M Brausi","year":"2002","unstructured":"Brausi M, Collette L, Kurth K et al (2002) Variability in the recurrence rate at first follow-up cystoscopy after TUR in stage Ta T1 transitional cell carcinoma of the bladder: a combined analysis of seven EORTC studies. Eur Urol 41:523\u2013531. https:\/\/doi.org\/10.1016\/s0302-2838(02)00068-4","journal-title":"Eur Urol"},{"key":"6025_CR39","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.urology.2018.04.039","volume":"118","author":"S Tapiero","year":"2018","unstructured":"Tapiero S, Helfand A, Kedar D et al (2018) Patient compliance with maintenance intravesical therapy for nonmuscle invasive bladder cancer. Urology 118:107\u2013113. https:\/\/doi.org\/10.1016\/j.urology.2018.04.039","journal-title":"Urology"},{"key":"6025_CR40","doi-asserted-by":"publisher","unstructured":"Musat MG, Kwon CS, Masters E, et al (2022) Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR). Clin Outcomes Res CEOR 14:35\u201348. https:\/\/doi.org\/10.2147\/CEOR.S341896","DOI":"10.2147\/CEOR.S341896"},{"key":"6025_CR41","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12885-024-12204-x","volume":"24","author":"J Luna","year":"2024","unstructured":"Luna J, Picker N, Wilke T et al (2024) Real-world evidence of treatment patterns and survival of metastatic gastric cancer patients in Germany. BMC Cancer 24:462. https:\/\/doi.org\/10.1186\/s12885-024-12204-x","journal-title":"BMC Cancer"},{"key":"6025_CR42","doi-asserted-by":"publisher","first-page":"6150","DOI":"10.3390\/cancers13246150","volume":"13","author":"T Datzmann","year":"2021","unstructured":"Datzmann T, Schmitt J, Fuhrmann S et al (2021) Implementation and effectiveness of novel therapeutic substances for advanced malignant melanoma in Saxony, Germany, 2010-2020-Cohort study based on administrative data. Cancers 13:6150. https:\/\/doi.org\/10.3390\/cancers13246150","journal-title":"Cancers"},{"key":"6025_CR43","doi-asserted-by":"publisher","first-page":"e060104","DOI":"10.1136\/bmjopen-2021-060104","volume":"12","author":"R Flemming","year":"2022","unstructured":"Flemming R (2022) Patterns of Pregabalin prescribing in four German federal states: analysis of routine data to investigate potential misuse of Pregabalin. BMJ Open 12:e060104. https:\/\/doi.org\/10.1136\/bmjopen-2021-060104","journal-title":"BMJ Open"},{"key":"6025_CR44","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s40120-019-00172-5","volume":"9","author":"S M\u00fcller","year":"2020","unstructured":"M\u00fcller S, Heidler T, Fuchs A et al (2020) Real-World treatment of patients with multiple sclerosis per MS subtype and associated healthcare resource use: an analysis based on 13,333 patients in Germany. Neurol Ther 9:67\u201383. https:\/\/doi.org\/10.1007\/s40120-019-00172-5","journal-title":"Neurol Ther"},{"key":"6025_CR45","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.nmd.2023.02.002","volume":"33","author":"A Mevius","year":"2023","unstructured":"Mevius A, J\u00f6res L, Biskup J et al (2023) Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul Disord NMD 33:324\u2013333. https:\/\/doi.org\/10.1016\/j.nmd.2023.02.002","journal-title":"Neuromuscul Disord NMD"},{"key":"6025_CR46","doi-asserted-by":"publisher","first-page":"e2126306","DOI":"10.1001\/jamanetworkopen.2021.26306","volume":"4","author":"S Wilkinson","year":"2021","unstructured":"Wilkinson S, Gupta A, Scheuer N et al (2021) Assessment of alectinib vs ceritinib in ALK-Positive Non-Small cell lung cancer in phase 2 trials and in Real-world data. JAMA Netw Open 4:e2126306. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.26306","journal-title":"JAMA Netw Open"},{"key":"6025_CR47","doi-asserted-by":"publisher","first-page":"2831","DOI":"10.1007\/s12325-022-02091-8","volume":"39","author":"AZ Torres","year":"2022","unstructured":"Torres AZ, Nussbaum NC, Parrinello CM et al (2022) Analysis of a Real-World progression variable and related endpoints for patients with five different cancer types. Adv Ther 39:2831\u20132849. https:\/\/doi.org\/10.1007\/s12325-022-02091-8","journal-title":"Adv Ther"},{"key":"6025_CR48","doi-asserted-by":"publisher","first-page":"684","DOI":"10.18553\/jmcp.2024.30.7.684","volume":"30","author":"DR Kaye","year":"2024","unstructured":"Kaye DR, Khilfeh I, Muser E et al (2024) Real-world economic burden associated with disease progression from metastatic castration-sensitive to castration-resistant prostate cancer on treatment in the united States. J Manag Care Spec Pharm 30:684\u2013697. https:\/\/doi.org\/10.18553\/jmcp.2024.30.7.684","journal-title":"J Manag Care Spec Pharm"},{"key":"6025_CR49","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1002\/cpt.3045","volume":"114","author":"SK Mhatre","year":"2023","unstructured":"Mhatre SK, Machado RJM, Ton TGN et al (2023) Real-World Progression-Free survival as an endpoint in lung cancer: replicating Atezolizumab and docetaxel arms of the OAK trial using Real-World data. Clin Pharmacol Ther 114:1313\u20131322. https:\/\/doi.org\/10.1002\/cpt.3045","journal-title":"Clin Pharmacol Ther"},{"key":"6025_CR50","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1002\/acr.25269","volume":"76","author":"T Beukelman","year":"2024","unstructured":"Beukelman T, Su Y, Xie F et al (2024) Using electronic health records and linked claims data to assess new medication use and primary nonadherence in rheumatology patients. Arthritis Care Res 76:550\u2013558. https:\/\/doi.org\/10.1002\/acr.25269","journal-title":"Arthritis Care Res"},{"key":"6025_CR51","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1097\/01.mlr.0000207817.32496.cb","volume":"44","author":"R Grymonpre","year":"2006","unstructured":"Grymonpre R, Cheang M, Fraser M et al (2006) Validity of a prescription claims database to estimate medication adherence in older persons. Med Care 44:471\u2013477. https:\/\/doi.org\/10.1097\/01.mlr.0000207817.32496.cb","journal-title":"Med Care"},{"key":"6025_CR52","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.18553\/jmcp.2019.25.12.1349","volume":"25","author":"MB Glassberg","year":"2019","unstructured":"Glassberg MB, Trygstad T, Wei D et al (2019) Accuracy of prescription claims data in identifying truly nonadherent patients. J Manag Care Spec Pharm 25:1349\u20131356. https:\/\/doi.org\/10.18553\/jmcp.2019.25.12.1349","journal-title":"J Manag Care Spec Pharm"},{"key":"6025_CR53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2016.11.008","volume":"122","author":"S Mueller","year":"2017","unstructured":"Mueller S, Wilke T, Bechtel B et al (2017) Non-persistence and non-adherence to long-acting COPD medication therapy: A retrospective cohort study based on a large German claims dataset. Respir Med 122:1\u201311. https:\/\/doi.org\/10.1016\/j.rmed.2016.11.008","journal-title":"Respir Med"},{"key":"6025_CR54","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/02770903.2021.1871738","volume":"59","author":"F Hardtstock","year":"2022","unstructured":"Hardtstock F, Maywald U, Timmermann H et al (2022) Extent of non-adherence and non-persistence in asthma patients: analysis of a large claims data set. J Asthma Off J Assoc Care Asthma 59:829\u2013839. https:\/\/doi.org\/10.1080\/02770903.2021.1871738","journal-title":"J Asthma Off J Assoc Care Asthma"},{"key":"6025_CR55","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1007\/s00417-024-06690-9","volume":"263","author":"J Krieger","year":"2025","unstructured":"Krieger J, Cox O, Flacke J-P et al (2025) Real-world therapy and persistence of patients with neovascular age-related macular degeneration and diabetic retinopathy or diabetic macular edema: a German claims data analysis. Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol 263:713\u2013725. https:\/\/doi.org\/10.1007\/s00417-024-06690-9","journal-title":"Graefes Arch Clin Exp Ophthalmol Albrecht Von Graefes Arch Klin Exp Ophthalmol"},{"key":"6025_CR56","unstructured":"FDA (2025) Real-World Evidence. https:\/\/www.fda.gov\/science-research\/science-and-research-special-topics\/real-world-evidence"},{"key":"6025_CR57","unstructured":"European Medicines Agency (EMA) (2024) Real-world evidence. https:\/\/www.ema.europa.eu\/en\/about-us\/how-we-work\/data-regulation-big-data-other-sources\/real-world-evidence"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-025-06025-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-025-06025-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T07:57:41Z","timestamp":1770883061000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-025-06025-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":57,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6025"],"URL":"https:\/\/doi.org\/10.1007\/s00345-025-06025-1","relation":{},"ISSN":["1433-8726"],"issn-type":[{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,1]]},"assertion":[{"value":"23 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"EO, HAB AK, ST, IH, LK are all employees of Pfizer Pharma GmbH in Germany, the sponsor of this study and may hold stocks or stock options. JL and ML participated in this study as staff members of Cytel, the work of IPAM and Cytel in this study was funded by Pfizer. NK received honoraria from Pfizer, Astellas, BMS, MSD, Merck, Janssen, Johnson&Johnson, Eisai, Bayer, Apogepha. MDS received honoraria and travel support from AAA, AbbVie, Amgen, Astellas, AstraZeneca, Basilea, Bayer, BMS, Daiichi Sankyo, EISAI, Ferring, Gilead, Immunomedics, Ipsen, Janssen, MSD, Merck, Novartis, Pfizer, Roche, Sandoz, Sanofi, SeaGen, Thermosome.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol was approved by a Scientific Committee, consisting of external experts, the cooperating sickness funds, the research sponsor, Cytel and IPAM. As the study analyzed retrospective anonymized claims data, the use of such data is not subject to ethics committee approval and no informed consent was required according to German laws (\u00a7\u00a075 SGB X, Tenth Social Code Book). The work on the dataset conformed to all social security data protection requirements. The study followed all the dictates of the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}],"article-number":"661"}}